IRIS
BERSANELLI, MELISSA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.358
AS - Asia 4.343
EU - Europa 2.568
SA - Sud America 907
AF - Africa 271
Continente sconosciuto - Info sul continente non disponibili 209
OC - Oceania 3
Totale 13.659
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.158
SG - Singapore 1.751
CN - Cina 694
BR - Brasile 661
VN - Vietnam 660
IE - Irlanda 586
IT - Italia 489
SE - Svezia 459
BD - Bangladesh 396
HK - Hong Kong 364
FR - Francia 201
DE - Germania 188
ZA - Sudafrica 177
NL - Olanda 151
AT - Austria 115
CA - Canada 81
FI - Finlandia 81
GB - Regno Unito 79
AR - Argentina 76
IN - India 75
RU - Federazione Russa 64
CO - Colombia 46
IR - Iran 46
TR - Turchia 46
EC - Ecuador 45
ID - Indonesia 45
IQ - Iraq 44
MX - Messico 42
VE - Venezuela 28
BE - Belgio 24
JP - Giappone 24
PH - Filippine 24
PK - Pakistan 21
MA - Marocco 19
PL - Polonia 19
UZ - Uzbekistan 19
CZ - Repubblica Ceca 18
PY - Paraguay 18
KR - Corea 17
UA - Ucraina 16
CI - Costa d'Avorio 13
EG - Egitto 13
ES - Italia 13
LT - Lituania 13
KE - Kenya 12
MY - Malesia 12
EE - Estonia 11
KZ - Kazakistan 11
AE - Emirati Arabi Uniti 10
CR - Costa Rica 10
SA - Arabia Saudita 10
TH - Thailandia 10
CL - Cile 9
GT - Guatemala 9
HN - Honduras 9
TW - Taiwan 9
BO - Bolivia 8
DO - Repubblica Dominicana 8
JO - Giordania 8
UY - Uruguay 8
NP - Nepal 7
PE - Perù 7
TN - Tunisia 7
PA - Panama 6
TT - Trinidad e Tobago 6
AL - Albania 5
BG - Bulgaria 5
ET - Etiopia 5
JM - Giamaica 5
OM - Oman 5
RS - Serbia 5
SN - Senegal 5
SV - El Salvador 5
AO - Angola 4
AZ - Azerbaigian 4
DZ - Algeria 4
IL - Israele 4
KW - Kuwait 4
PS - Palestinian Territory 4
RO - Romania 4
AU - Australia 3
BB - Barbados 3
BH - Bahrain 3
BS - Bahamas 3
DK - Danimarca 3
KG - Kirghizistan 3
LB - Libano 3
MD - Moldavia 3
NG - Nigeria 3
NI - Nicaragua 3
PR - Porto Rico 3
QA - Qatar 3
CH - Svizzera 2
GP - Guadalupe 2
HR - Croazia 2
HU - Ungheria 2
KH - Cambogia 2
KN - Saint Kitts e Nevis 2
BA - Bosnia-Erzegovina 1
BF - Burkina Faso 1
Totale 13.424
Salva come PNG Salva come JPEG
Città #
Ashburn 863
Singapore 828
San Jose 605
Dublin 580
Chandler 464
Santa Clara 425
Hong Kong 356
Council Bluffs 240
Ho Chi Minh City 213
Boardman 189
Dallas 174
Beijing 171
Johannesburg 156
Hanoi 150
New York 137
Lauterbourg 123
Princeton 113
Vienna 109
Shanghai 106
Los Angeles 104
Ann Arbor 79
Munich 69
São Paulo 64
Milan 59
Helsinki 55
Buffalo 47
Tehran 38
Rome 37
Columbus 34
Rio de Janeiro 33
Frankfurt am Main 31
Parma 31
Chicago 30
Moscow 30
Bremen 28
Phoenix 27
North Bergen 26
Wilmington 26
Bologna 25
Da Nang 25
Des Moines 25
Turku 25
The Dalles 24
Haiphong 23
Jakarta 23
Toronto 23
Brussels 22
Atlanta 21
Nuremberg 21
Brooklyn 20
Orem 19
Belo Horizonte 18
Montreal 18
Seattle 18
Guayaquil 17
Quito 17
Brasília 16
Guangzhou 16
London 16
Naples 16
Stockholm 15
Tashkent 15
Baghdad 14
Boston 14
Hefei 14
Tianjin 14
Warsaw 14
Abidjan 13
Chennai 13
Curitiba 13
Houston 13
Tokyo 13
Dearborn 12
Bogotá 11
Hải Dương 11
Medellín 11
Verona 11
Asunción 10
Charlotte 10
Denver 10
Düsseldorf 10
Jacksonville 10
Marseille 10
Nanjing 10
Brno 9
Dhaka 9
Lahore 9
Modena 9
Nairobi 9
San Francisco 9
Vancouver 9
Ankara 8
Bari 8
Biên Hòa 8
Buenos Aires 8
Montevideo 8
Pasadena 8
Poplar 8
Pune 8
San José 8
Totale 7.724
Salva come PNG Salva come JPEG
Nome #
Correlations between tumor-infiltrating and circulating lymphocyte subpopulations in advanced renal cancer patients treated with nivolumab 220
The Prognostic Role of High Blood Cholesterol in Advanced Cancer Patients Treated With Immune Checkpoint Inhibitors 216
PREDICTIVE AND PROGNOSTIC VALUE OF CLINICAL AND MOLECULAR FEATURES IN PATIENTS UNDERGOING PULMONARY METASTASECTOMY FROM RENAL CELL CARCINOMA 206
Antibiotic-dependent effect of probiotics in patients with non-small cell lung cancer treated with PD-1 checkpoint blockade 205
Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events 202
The role of blood cholesterol quality in patients with advanced cancer receiving immune checkpoint inhibitors 192
INfluenza Vaccine Indication during therapy with Immune checkpoint inhibitors: A multicenter prospective observational study (INVIDIa-2) 189
Real World Analysis of Peritoneal Metastasis From Renal Cell Carcinoma. Meet-Uro27 186
Review on radiological evolution of COVID-19 pneumonia using computed tomography 167
Retrospective immunophenotypical evaluation of MET, PD-1/PD-L1, and mTOR pathways in primary tumors and pulmonary metastases of renal cell carcinoma: the RIVELATOR study addresses the issue of biomarkers heterogeneity 166
1929O Soluble PD-L1 and circulating CD8+PD1+ and NK cells enclose a highly prognostic and predictive immune effector score in immunotherapy treated NSCLC patients 165
The Urinary Microbiome and Anticancer Immunotherapy: The Potentially Hidden Role of Unculturable Microbes 161
PD-L1 SNPs as biomarkers to define benefit in patients with advanced NSCLC treated with immune checkpoint inhibitors 161
Soluble PD-L1 and Circulating CD8+PD-1+ and NK Cells Enclose a Prognostic and Predictive Immune Effector Score in Immunotherapy Treated NSCLC patients 156
Immune context characterization and heterogeneity in primary tumors and pulmonary metastases from renal cell carcinoma 156
Clinical Impact of COVID-19 Outbreak on Cancer Patients: A Retrospective Study 153
Palliative radiotherapy in advanced cancer patients treated with immune-checkpoint inhibitors: The practice study 152
Author Correction: Validation of the GRade, Age, Nodes and Tumor (GRANT) score within the Surveillance Epidemiology and End Results (SEER) database: A new tool to predict survival in surgically treated renal cell carcinoma patients (Scientific Reports, (2019), 9, 1, (13218), 10.1038/s41598-019-49250-6) 151
1462P Clinical outcome of patients with non-clear metastatic renal cell carcinoma treated with pembrolizumab-axitinib combination: NEMESIA (non-clear metastatic renal cell carcinoma pembrolizumab axitinib) study, a subgroup analysis of I-RARE observational study (Meet-URO 23a) 146
Asymptomatic pulmonary embolism in lung cancer: Prevalence and analysis of clinical and radiological characteristics in 141 outpatients 145
Circulating immune-profile as predictor of outcome in advanced NSCLC patients treated with Nivolumab 145
Anaplastic lymphoma kinase as a new target for the treatment of non-small-cell lung cancer 144
Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: The multicenter retrospective CLARITY study 138
Differential diagnosis of COVID-19 at the chest computed tomography scan: A review with special focus on cancer patients 136
Assessing the effectiveness and safety of lenvatinib and everolimus in advanced renal cell carcinoma: insights from the RELIEVE study’s analysis of heavily pretreated patients 133
Clinical impact of COVID-19 in a single-center cohort of a prospective study in cancer patients receiving immunotherapy 130
Predictive ability of a drug-based score in patients with advanced non–small-cell lung cancer receiving first-line immunotherapy 128
Renal cell carcinoma and viral infections: A dangerous relationship? 127
Prognostic value of 18F-FDG standard uptake value by integrated PET/CT in the staging of malignant pleural mesothelioma 126
Clinical and hematologic parameters address the outcomes of non-small-cell lung cancer patients treated with nivolumab 126
The right immune-modulation at the right time: thymosin α1 for prevention of severe COVID-19 in cancer patients 125
Validation of a Novel Three-Dimensional (3D Fusion) Gross Sampling Protocol for Clear Cell Renal Cell Carcinoma to Overcome Intratumoral Heterogeneity: The Meet-Uro 18 Study 125
Cabozantinib in metastatic renal cell carcinoma: Latest findings and clinical potential 123
Symptomatic COVID-19 in advanced-cancer patients treated with immune-checkpoint inhibitors: prospective analysis from a multicentre observational trial by FICOG 122
Cabozantinib in the elderly with metastatic renal cell carcinoma undergoing geriatric G8 screening test: A prospective multicenter observational study (ZEBRA/MEET-URO 9) 120
The effect of COVID-19 emergency in the management of melanoma in Italy 120
Impact of influenza syndrome and flu vaccine on survival of cancer patients during immunotherapy in the INVIDIa study 120
Gefitinib plus interleukin-2 in advanced non-small cell lung cancer patients previously treated with chemotherapy 120
Treatment Outcome of metastatic lesions from renal cell carcinoma underGoing Extra-cranial stereotactic body radioTHERapy: The together retrospective study 120
BOLERO-3 results: Pharmacological activity or pharmacokinetic effect? 117
Feasibility, Safety, and Efficacy of an Alternative Schedule of Sunitinib for the Treatment of Patients with Metastatic Renal Cell Carcinoma: A Retrospective Study 117
Retroperitoneal cystoadenocarcinoma: A case report with a literature review 116
Immunotherapy and Sonpavde score validation in advanced upper tract urothelial carcinoma: a retrospective study by the Italian Network for Research in Urologic-Oncology 116
Systematic vitamin D supplementation is associated with improved outcomes and reduced thyroid adverse events in patients with cancer treated with immune checkpoint inhibitors: results from the prospective PROVIDENCE study 114
Antiangiogenic tyrosine kinase inhibitors and immunotherapy as first-line treatment for metastatic renal cell carcinoma: is there an increased risk of hypothyroidism? 113
Avelumab Maintenance for Urothelial Carcinoma 113
A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: When overweight becomes favorable 111
Cabozantinib in RCC: only a METEOR or a rising star? 109
Benefit of adjuvant immunotherapy in renal cell carcinoma: A myth or a reality? 107
A metanalysis on cabozantinib and bone metastases: True story or commercial gimmick? 106
Clinical outcomes of NSCLC patients experiencing early immune-related adverse events to PD-1/PD-L1 checkpoint inhibitors leading to treatment discontinuation 106
Clinical use of lenvatinib in combination with everolimus for the treatment of advanced renal cell carcinoma 106
Everolimus in the management of metastatic renal cell carcinoma: An evidence-based review of its place in therapy 105
Correction to: Feasibility, Safety, and Efficacy of an Alternative Schedule of Sunitinib for the Treatment of Patients with Metastatic Renal Cell Carcinoma: A Retrospective Study (Drugs in R&D, (2017), 17, 4, (585-596), 10.1007/s40268-017-0209-5) 104
Primary Retroperitoneal Cystoadenocarcinoma: A Systematic Review 104
Effect of systemic therapies or best supportive care after disease progression to both nivolumab and cabozantinib in metastatic renal cell carcinoma: The Meet‐Uro 19BEYOND study 104
Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study 103
Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients 103
Immunological insights on influenza infection and vaccination during immune checkpoint blockade in cancer patients 103
Patient performance status and cancer immunotherapy efficacy: a meta-analysis 103
A systematic review and meta-analysis on the Optimal Treatment duration of cHEckpoint inhibitoRS in solid tumors: the OTHERS study 102
Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index 102
Clinical Outcomes and Toxic Effects of Single-Agent Immune Checkpoint Inhibitors among Patients Aged 80 Years or Older with Cancer: A Multicenter International Cohort Study 102
Chemotherapy in metastatic renal cell carcinoma today? A systematic review 100
Autophagic gene polymorphisms in liquid biopsies and outcome of patients with metastatic clear cell renal cell carcinoma 99
First-line pazopanib in patients with advanced non-clear cell renal carcinoma: An Italian case series 98
Discontinuation of anti-PD1 in advanced melanoma: an observational retrospective study from the Italian Melanoma Intergroup 98
Evaluating the role of FAMIly history of cancer and diagnosis of multiple neoplasms in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: the multicenter FAMI-L1 study 96
The outcome to axitinib or everolimus after sunitinib in metastatic renal cell carcinoma 96
Pazopanib as a possible option for the treatment of metastatic non-clear cell renal carcinoma patients: a systematic review 95
Capter 4 - Adjuvant Therapy for Renal Cell Carcinoma 94
MDM2 gene amplification as selection tool for innovative targeted approaches in PD-L1 positive or negative muscle-invasive urothelial bladder carcinoma 94
Outcome and Safety of Sorafenib in Metastatic Renal Cell Carcinoma Dialysis Patients: A Systematic Review 93
A systematic review on the emerging association between the occurrence of immune-related adverse events and clinical outcomes with checkpoint inhibitors in advanced cancer patients 93
GU-CA-COVID: a clinical audit among Italian genitourinary oncologists during the first COVID-19 outbreak 93
The 'nivolution' in renal cell carcinoma: Behind the scenes of clinical trials 90
Spotlight on cabozantinib for previously untreated advanced renal cell carcinoma: Evidence to date 89
Prognostic significance of host immune status in patients with late relapsing renal cell carcinoma treated with targeted therapy 88
Impact of influenza vaccination on survival of patients with advanced cancer receiving immune checkpoint inhibitors (INVIDIa-2): final results of the multicentre, prospective, observational study 86
Reassessing Human Adipose Tissue 86
PD-1/PD-L1 checkpoint inhibitors during late stages of life: an ad-hoc analysis from a large multicenter cohort 85
Cytoreductive nephrectomy in the era of targeted- And immuno- therapy for metastatic renal cell carcinoma: An elusive issue? A systematic review of the literature 84
Corrigendum: Validation of a new prognostic model to easily predict outcome in renal cell carcinoma: The GRANT score applied to the ASSURE trial population [Ann Oncol., 28, (2017) (2747-2753)] DOI: 10.1093/annonc/mdx492 83
Metastatic Renal Cell Carcinoma Rapidly Progressive to Sunitinib: What to Do Next? 83
Validation of a Novel Three-Dimensional (3D Fusion) Gross Sampling Protocol for Clear Cell Renal Cell Carcinoma to Overcome Intratumoral Heterogeneity: The Meet-Uro 18 Study 82
Family history of cancer as surrogate predictor for immunotherapy with anti-PD1/PD-L1 agents: Preliminary report of the FAMI-L1 study 82
Inflammatory indices and clinical factors in metastatic renal cell carcinoma patients treated with nivolumab: the development of a novel prognostic score (Meet-URO 15 study) 82
Predictive Ability for Disease-Free Survival of the GRade, Age, Nodes, and Tumor (GRANT) Score in Patients with Resected Renal Cell Carcinoma 81
Clinical Outcomes of Patients With Metastatic Urothelial Carcinoma After Progression to Immune Checkpoint Inhibitors: A Retrospective Analysis by the Meet-Uro Group (Meet-URO 1 Study) 80
“Finding NEMO” in NRAS-mutant melanoma: a step towards a sequential strategy? 80
Immunotherapy-based combinations versus standard first-line treatment for metastatic clear cell renal cell carcinoma: a systematic review and meta-analysis 80
Gefitinib and afatinib treatment in an advanced non-small cell lung cancer (NSCLC) patient undergoing hemodialysis 79
Outcome of patients with advanced upper tract urothelial carcinoma treated with immune checkpoint inhibitors: A systematic review and meta-analysis 79
First-Line PAzopanib in NOn–clear-cell Renal cArcinoMA: The Italian Retrospective Multicenter PANORAMA Study 78
Role of Bone Metastases in Patients Receiving Immunotherapy for Pre-Treated Urothelial Carcinoma: The Multicentre, Retrospective Meet-URO-1 Bone Study 77
Validation of the GRade, Age, Nodes and Tumor (GRANT) score within the Surveillance Epidemiology and End Results (SEER) database: A new tool to predict survival in surgically treated renal cell carcinoma patients 77
Using peripheral immune-inflammatory blood markers in tumors treated with immune checkpoint inhibitors: An INVIDIa-2 study sub-analysis 76
Pembrolizumab Plus Axitinib for Metastatic Papillary and Chromophobe Renal Cell Carcinoma: NEMESIA (Non Clear MEtaStatic Renal Cell Carcinoma Pembrolizumab Axitinib) Study, a Subgroup Analysis of I-RARE Observational Study (Meet-URO 23a) 76
Pathological nodal staging score for renal cell carcinoma: How to build reliable therapeutic choices basing on assumptions 76
Can we identify a preferred first-line strategy for sarcomatoid renal cell carcinoma? A network meta-analysis 76
Totale 11.693
Salva come PNG Salva come JPEG
Categoria #
all - tutte 57.034
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 57.034
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022479 0 0 0 0 6 3 160 45 28 6 40 191
2022/20231.984 239 222 118 123 146 224 12 99 691 13 71 26
2023/2024743 39 64 21 20 61 152 52 45 32 44 86 127
2024/20252.642 38 154 195 111 226 351 128 120 263 346 199 511
2025/20265.999 472 476 638 601 846 248 550 171 672 493 520 312
2026/20271.401 151 258 351 640 1 0 0 0 0 0 0 0
Totale 13.659